Leukemia

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway

[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

QOL, Fatigue, but Not Physical Performance, Return to Normal After AML Treatment

By

In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

By

FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

Weekend Admission for Acute Leukemia Negatively Affects Mortality Rate

By

An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

Dexrazoxane May Reduce Cardiotoxicity in Pediatric AML

By

Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

Developing Multidisciplinary Algorithm for AML Induction in Elderly Benefits Nurses

By

Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

Symptoms, Quality of Life May Improve During Hospitalization for Acute Leukemia

By

Results of a prospective, longitudinal study presented at 2018 ONS Congress demonstrate improvement from baseline to discharge patients with acute leukemia who receive induction chemotherapy in hospital.

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

FDA Approves Blincyto for B-Cell Precursor ALL in Remission With MRD Presence

By

Accelerated approval was granted by the FDA based on the results of a single-arm trial.

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

Class Preps Patients With AML for Successful At-Home Symptom Management and Self-Care

By

A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax Found Effective in Relapsed/Refractory Chronic Lymphocytic Leukemia

By

A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

Intensified Reduced-Intensity Conditioning May Improve Outcomes in CBT

By

Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?

[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

Elevated Pre-HCT Iron Levels Predictive of Worse Survival Outcomes in AML/MDS

By

The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

1-year Imatinib or Nilotinib Therapy Not Associated with Cardiotoxity in CML

By

Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

Risk of Secondary Cancers With CML Linked to Disease, Not Treatment

By

This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

By

The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.

Venetoclax plus rituximab increases progression-free survival in relapsed chronic lymphocytic leukemia

1. Patients with relapsed or remitting chronic lymphocytic leukemia (CLL) treated with venetoclax-rituximab had a greater 2-year progression-free survival rate compared to bendamustine-rituximab treated patients. 2. Progression-free survival rates were greater for venetoclax-rituximab patients in almost all subgroup analysis, including patients with chromosome 17p deletion. Evidence Rating Level: 1 (Excellent) Study Rundown: Curative treatment of relapsed []

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

Overtreatment a Concern With RAI for Well-Differentiated Thyroid Cancer

By

In a study from the Cleveland Clinic, researchers investigated the association between well-differentiated thyroid cancer and risk for AML or CML in those patients treated with radioactive iodine.

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

Secondary Outcome Shows Inotuzumab Ozogamicin for B-cell ALL Improves Health-Related QOL

By

Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

FDA Expands Nilotinib Indication to Include Pediatric Chronic Myeloid Leukemia

By

Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

Treatment-Free Remission in Chronic Phase CML Achieved With First-Line Nilotinib

By

Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

Chronic Lymphocytic Leukemia Responds Better to Obinutuzumab Than Other Monoclonal Antibodies

By

Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

Second-line Nilotinib May Lead to Treatment-Free Remission in Chronic Phase CML

By

Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.

Monitoring Patients With Chronic Lymphocytic Leukemia  Treated With Venetoclax

Monitoring Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax

By

What are key monitoring guidelines for patients with CLL being treated with venetoclax?

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

By

Results of a triple-blind study demonstrate effectiveness of zinc sulfate in preventing chemotherapy-induced mucositis or reducing its incidence and severity in patients with leukemia receiving chemotherapy.

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

By

A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs